Your Patient Choice is creating a new NHS technology-enabled healthcare provider for both mental and physical health. We are driven by the vision of making free NHS healthcare accessible and higher quality for patients, and more affordable for the NHS. We are unique as: We have built our own innovative patient-centred care pathways. These are delivered by our internal clinical teams using our in-house technology platform. Our founders (medical doctor Mark Jenkins and healthcare entrepreneur Darshak Shah) have previously built tech-enabled providers in NHS obesity and ophthalmology care (treating over 1 million patients in the last 10 years), and want to bring these lessons to all outpatient specialties. We are able to move fast as we have raised funds from leading healthcare investors Triple Point and Heal Capital, as well as expert angels who deeply understand the NHS. Our first service, autism assessments for children and teens, is launching soon, and will be followed by ADHD assessments and treatment for children and teens, and dementia assessments and treatment for adults. We know 184,000 people are waiting 2-10 years for an NHS autism assessment today, and we need your help to shorten this wait! (https://www.autism.org.uk/what-we-do/news/autism-assessment-waiting-times-6)
Your Patient Choice is a new independent provider of NHS services, driven by the vision of making high-quality healthcare accessible for patients and affordable for the NHS. They're on a mission to fix the broken healthcare system and the good news is that they're hiring for a whole host of brilliant roles. If you're looking for a meaningful role in the healthcare space, then it's well worth checking them out.
Working hours
Flex hours
Nomad friendly
UK - remote
Enhanced holidays
25-30 days holiday
Paid sabbaticals
Paid sabbatical > every 5 year...
Equity
Equity included in package
Enhanced pension
>5% Pension
Equipment budget
Enhanced tech budget
This employer is not currently hiring.
Sign up for an alert to find out when they are next hiring.